Indigenous CBD oral dosage forms
The present invention is a cannabidiol oral dosage form including predominantly or exclusively hemp pomace, compounded as a tablet or formulated within a capsule without the addition of synthetic excipients, fillers or other additives, not including the inevitable presence of some moisture and the optional presence of fungal or bacterial probiotics introduced prior to or during dosage form manufacturing, and with or without fermentation of the hemp pomace prior to the dosage form manufacturing process. The dosage forms contain dietary fiber, important to activity as the desired delivery system, having a ratio of one part soluble dietary fiber to 30 parts insoluble dietary fiber and delivers desirable/non hallucinogenic cannabinoids (CBD, CBG) in a ratio of 30:1 up to 120:1 to hallucinogenic cannabinoids (THC).
1. A cannabinoid oral dosage form in unit dosage form, consisting essentially of hemp pomace, compounded as a tablet or within a capsule, powder or other unit dosage form as the predominant or exclusive ingredient, wherein said hemp pomace is the resulting material remaining after extraction and removal of cannabinoids therefrom, and having a soluble dietary fiber to insoluble dietary fiber ratio of 1:30 and a maximum cannabinoid dose per unit dosage form of 25 mg.
2. A cannabinoid oral dosage form in unit dosage form, consisting essentially of hemp pomace, compounded as a tablet or within a capsule, powder or other unit dosage form as the predominant or exclusive ingredient, wherein said hemp pomace is the resulting material remaining after extraction and removal of cannabinoids therefrom, and having a ratio of non hallucinogenic/addictive cannabinoid (CBD or CBG) to THC of 30:1-120:1.
3. The oral dosage form of claim 1 , wherein each oral dosage form contains less than 10% water as moisture and wherein said cannabinoid is one or more of cannabidiol, cannabigerol, cannabidivarin, cannabichromene, or cannabinol.
4. The oral dosage form of claim 1 , wherein said hemp pomace is fermented with a bacteria or fungus prior to compounding.
5. The oral dosage form of claim 1 , wherein said dosage form contains no more than 10 mg cannabinoid per unit dosage form.